Navigation Links
Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
Date:4/14/2008

SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in combination with rapamycin in a renal cell carcinoma mouse model. The combination of SF1126 (20 mg/kg i.v., 3x/week) with rapamycin (1.5 mg/kg i.p., 3x/week) administered simultaneously showed a 54 percent regression of the tumor volume versus starting tumor volume. This efficacy was significantly better than treatment with either agent alone or where the two agents were administered sequentially.

Angiogenesis plays a major role in the progression of renal cell carcinoma, and SF1126 was shown to dose-dependently inhibit endothelial cell proliferation in an in vitro model, while the mTOR inhibitor rapamycin (sirolimus) had no significant effect. SF1126 also showed dose-dependent cell signal (pAkt) inhibition in both renal cell carcinoma cells and endothelial cells under stimulation conditions using the growth factors IGF, VEGF and Bv8.

"There is significant biological rationale for combining targeted therapeutic agents in oncology to improve efficacy," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "The combination of SF1126, our lead product candidate, with rapamycin exhibited synergistic anticancer effects, and this increased effect was optimal when the agents were administered in combination as opposed to sequentially. SF1126 is currently in Phase I clinical trials in both solid tumors and multiple myeloma."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is tho
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
2. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
3. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
4. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
5. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
6. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
7. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
10. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Lockton Dunning Benefits, the Dallas ... of Vice President Kim Foerster on ... team, Excelsior Solutions. Foerster brings ... position.  Most recently, she worked as the Director ... where she has held various managerial positions since ...
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
(Date:12/22/2014)... , Dec. 22, 2014   TRU-D SmartUVC ... UV disinfection robot, announced today that the General Services ... through November 2019.   This newly formed ... all levels of government purchasers, including Department of Veteran ... as Homeland Security contacts purchasing solutions for the Ebola ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 2011 /PRNewswire-iReach/ --  Janet R. Dees, CEO/President of ... opening of its newest vascular access center in Columbus, ... success for American Vascular Access, LLC., and the addition ... R. Dees, CEO/President.   "Our goal has continued ...
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... of its CLS® Brevius ™ Hip Stem with ... new technology enables surgeons to better match patients, individual ... adjustments. "Following its introduction in Europe earlier ...
Cached Medicine Technology:American Vascular Access Continues Growth in Georgia 2Zimmer Introduces New CLS® Brevius™ Hip Stem with Kinectiv® Technology in the United States 2Zimmer Introduces New CLS® Brevius™ Hip Stem with Kinectiv® Technology in the United States 3
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry ... affordable quality regarding heating, cooling and plumbing services in ... by the “Queen of Clean” for impressive contractor services ... reputation over the years for providing outstanding quality customer ... contractor services for both homeowners and businesses. Linda Cobb, ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... Susan Lark, MD, noted medical researcher and women,s health practitioner, has ... Reclast, as well as other oral bisphosphonates such as Boniva, Actonel, ... ... 2008 -- Susan Lark, MD , noted medical researcher and ...
... doctors urge everyone to kick the habit , , THURSDAY, ... Month in November, female smokers should take advantage of ... steps toward kicking the habit, urges The American College ... smoking takes an average of 14.5 years off women,s ...
... study finds , , THURSDAY, Nov. 27 (HealthDay News) -- ... sugar-sweetened drinks from school cafeteria menus will have little ... Because these drinks are believed to be a ... the United States, many schools across the nation are ...
... 27 The Committee for Human,Medicinal Products ... approval,for once-daily dosing of 800 mg PREZISTA(R) ... therapy in treatment-naive adults (those who,have never ... inhibitor, was,developed by Tibotec Pharmaceuticals, and Tibotec, ...
... /PRNewswire-Asia-FirstCall/ -- China,s leading,integrated medical device and healthcare ... "the Company", Stock Code: 8180.HK) is,pleased to announce ... Investment Management Limited ("Atlantis Investment") as financial,investors through ... at a price,HK$1.03 per share. , ...
... to benefit healthcare services for seasonal vineyard workers and their families. ... preview outstanding 2007 vintage. , ... Portland, OR (PRWEB) ... Noir Auction contributed generously to the 17th annual benefit with animated ...
Cached Medicine News:Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 2Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 3Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 4Health News:Women Smokers Lose 14.5 Years Off Life Span 2Health News:School Soda Ban Has Limited Effect 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 3Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 4Health News:Golden Meditech Brings in Financial Investor Through New Share Issuance 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 3
... Siemens introduces the AXIOM Artis ... first biplane magnetic navigation system equipped ... both planes, which is uniquely capable ... of catheter-based procedures to facilitate increased ...
... AXIOM Artis dTC is a versatile ... the cardiology department from preparation to ... interventional procedures. With AXIOM Artis dTC, your ... the cardiology department that leaves you free ...
The AXIOM Artis TC is ideal for applications above and beyond standard cardioangiography, and features:, Single plane C-Arm, ceiling-mounted, Full-size CCD camera, ...
... AXIOM Artis BC is a ... system architecture ideal for cardiological ... and ergonomic architecture enables you ... configuration to focus on:, ...
Medicine Products: